Skip to main content
Premium Trial:

Request an Annual Quote

Geron and Biolex Therapeutics Awarded US Patents

Premium
Geron has been awarded US Patent 7,326,572, “Endoderm cells from human embryonic stem cells.”
 
The inventors listed on the patent are Gregory Fisk and Margaret Inokuma.
 
The patent describes a system for producing pancreatic islet cells from embryonic stem cells, according to the abstract. Differentiation is initiated towards endoderm cells, and focused using reagents that promote the emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.
 

 
Biolex Therapeutics has been awarded US Patent 7,326,385, “Plate and method for high throughput screening.”
 
The inventor listed on the patent is Keith Everett.
 
A multiwell plate and method for media exchange is provided by the patent, the abstract stated. The cell wells are each connected via a channel to one of several aspiration holes. The wells contain a porous, hydrophilic frit, which is suspended on a ledge above a reservoir of fluid media and supports a tissue sample. The frit wicks the fluid media upwards to supply the tissue sample with nutrients. Old media is aspirated from the wells by a liquid handling device which inserts a pipette tip into the aspiration holes. The pipette tip suctions the media out of the cell well, through the channel, into the aspiration hole, and out through the pipette tip. New media is dispersed through the pipette tip and directly into the cell well.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.